No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
109 |
4. Check minimum number of eventsNone |
109 |
5. Include endpointsNone |
109 |
6. Filter based on genotype QC (FinnGen only) |
98 |
Control definitions (FinnGen only)
- Control exclude
- F5_SLEEP
Extra metadata
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Nightmares
based on the number of shared cases.
Similar with more cases:
- Nonorganic sleeping disorders
- Nonorganic sleeping disorders, excluding more controls
- Sleep disorders
- Behavioural syndromes associated with physiological disturbances and physical factors
- Sleep disorders (combined)
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 528 | 298 | 223 |
| Only index persons | 483 | 282 | 201 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 30.77 | 29.91 | 31.65 |
| Only index persons | 31.02 | 29.91 | 32.57 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 98 | 72 | 26 |
| Unadjusted period prevalence (%) | 0.02 | 0.03 | 0.01 |
| Median age at first event (years) | 43.69 | 36.02 | 64.91 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 105
- Matched controls
- 1050
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
F51.5
ICD-10 Finland
Nightmares
+∞
151.4
105
*
F51.0
ICD-10 Finland
Nonorganic insomnia
+∞
63.0
54
*
IAB13
NOMESCO Finland
Psychiatric sleep disorder consultation
+∞
36.6
33
*
N05AH04
ATC
quetiapine; oral
8.9
28.8
55
115
IEY18
NOMESCO Finland
Psychiatric sleep coaching, individual
+∞
27.3
25
*
N06AX11
ATC
mirtazapine; oral
7.6
24.6
64
179
IEY05
NOMESCO Finland
Dedicated profession-specific psychiatric intervention, individual
22.3
22.5
33
21
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
7.9
22.2
40
76
N06AX16
ATC
venlafaxine; oral
7.7
21.6
40
78
G47.3
ICD-10 Finland
Sleep apnoea
6.7
19.5
43
99
P06
ICPC
Sleep disturbance
7.1
18.2
34
66
N06AX26
ATC
vortioxetine; oral
8.1
17.8
28
45
G25.8
ICD-10 Finland
Other specified extrapyramidal and movement disorders
34.2
17.3
22
8
F33.2
ICD-10 Finland
Recurrent depressive disorder, current episode severe without psychotic symptoms
8.6
16.5
24
35
F32.9
ICD-10 Finland
Depressive episode, unspecified
6.3
16.1
34
74
N06AX12
ATC
bupropion; oral
7.0
16.0
29
54
F51.9
ICD-10 Finland
Nonorganic sleep disorder, unspecified
35.7
14.4
18
6
N05CF01
ATC
zopiclone; oral
5.0
13.9
43
129
ICB01
NOMESCO Finland
Psychiatric treatment plan, standard
13.2
13.6
24
23
N05BA04
ATC
oxazepam; oral
4.7
13.6
48
160
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
6.5
13.2
25
48
IDY03
NOMESCO Finland
Systematic individual therapy, cognitive-behavioural
12.1
13.1
24
25
IBA03
NOMESCO Finland
Psychotherapy evaluation
28.6
12.9
17
7
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
6.5
12.7
24
46
N06AB04
ATC
citalopram; systemic
5.0
12.5
35
96
N05CF02
ATC
zolpidem; oral
5.4
12.2
29
69
N06AX21
ATC
duloxetine; oral
5.3
11.7
28
67
N06AB10
ATC
escitalopram; oral
4.1
11.4
47
172
N06AB03
ATC
fluoxetine; oral
5.5
11.2
25
56
ICZ03
NOMESCO Finland
Participation in compiling a psychiatric treatment plan
13.4
11.1
19
17
N03AX16
ATC
[U] pregabalin
4.6
10.6
31
87
N06AX05
ATC
trazodone; oral
36.7
10.6
13
*
F51.3
ICD-10 Finland
Sleepwalking [somnambulism]
+∞
10.6
10
*
IBZ01
NOMESCO Finland
Profession-specific psychiatric evaluation
13.3
10.5
18
16
N03AE01
ATC
clonazepam; systemic
12.5
10.3
18
17
N06AX22
ATC
agomelatine; oral
15.5
10.1
16
12
ICC04
NOMESCO Finland
Psychiatric treatment plan, permanent discontinuation
11.8
10.0
18
18
G47.8
ICD-10 Finland
Other sleep disorders
11.8
10.0
18
18
IAA01
NOMESCO Finland
Assessment of need for psychiatric treatment
13.3
10.0
17
15
Z71.8
ICD-10 Finland
Other specified counselling
3.7
9.9
59
272
F33.9
ICD-10 Finland
Recurrent depressive disorder, unspecified
8.8
9.8
21
29
ZY010
NOMESCO Finland
Hospital outpatient
6.0
9.8
19
37
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
5.9
9.5
19
38
IGY02
NOMESCO Finland
Psychiatric monitoring contact
10.6
9.5
18
20
C07AA05
ATC
propranolol; systemic
3.8
9.5
39
140
IGY01
NOMESCO Finland
Accelerated psychiatric treatment contact
13.2
9.4
16
14
P01
ICPC
Feeling anxious/nervous/tense
3.8
9.4
41
153
A04
ICPC
Weakness/tiredness general
3.9
9.3
36
124
N04BC05
ATC
pramipexole; oral
8.3
8.7
19
27
F41.9
ICD-10 Finland
Anxiety disorder, unspecified
4.1
8.7
29
89
G47.9
ICD-10 Finland
Sleep disorder, unspecified
12.3
8.6
15
14
F43.1
ICD-10 Finland
Post-traumatic stress disorder
8.5
8.4
18
25
N05BA12
ATC
alprazolam; oral
5.4
8.2
18
39
N03AX12
ATC
[U] gabapentin; oral
4.3
8.0
24
68
N05AH03
ATC
olanzapine; systemic
7.5
7.8
18
28
ICB03
NOMESCO Finland
Psychiatric treatment plan, monitoring
20.2
7.8
11
6
N02BF01
ATC
gabapentin; oral
5.1
7.8
18
41
P76
ICPC
Depressive disorder
4.8
7.6
19
46
P74
ICPC
Anxiety disorder/anxiety state
6.6
7.5
19
34
IFA01
NOMESCO Finland
Psychiatric pharmacotherapy plan, not specified
17.3
7.4
11
7
G47.2
ICD-10 Finland
Disorders of the sleep-wake schedule
+∞
7.4
7
*
ICB02
NOMESCO Finland
Psychiatric treatment plan, extended/prolonged
21.9
7.3
10
5
N06AB06
ATC
sertraline; oral
3.8
7.2
26
84
ZXE13
NOMESCO Finland
Procedure duration 90 to 119 minutes
7.7
7.1
16
24
IBA01
NOMESCO Finland
Diagnostic and symptom-mapping evaluation
15.2
7.1
11
8
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
4.1
7.0
22
64
N05AX12
ATC
aripiprazole; systemic
6.2
6.9
18
34
F32.3
ICD-10 Finland
Severe depressive episode with psychotic symptoms
24.4
6.8
9
*
AA400
NOMESCO Finland
Electroconvulsive therapy
24.4
6.8
9
*
F32.1
ICD-10 Finland
Moderate depressive episode
4.5
6.8
18
46
F51
ICD-10 Finland
Nonorganic sleep disorders
8.6
6.3
13
17
IER01
NOMESCO Finland
Psychoeducation, group
28.6
6.3
8
*
IDY30, ,
NOMESCO Finland
+∞
6.3
6
*
G47.0
ICD-10 Finland
Disorders of initiating and maintaining sleep [insomnias]
+∞
6.3
6
*
N06AB05
ATC
paroxetine; oral
6.3
6.3
16
29
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
6.3
6.3
16
29
IBA04
NOMESCO Finland
Extensive initial psychiatric evaluation
13.6
6.2
10
8
F41.1
ICD-10 Finland
Generalized anxiety disorder
4.1
6.2
19
54
ZYC01
NOMESCO Finland
Remote contact by phone
5.8
6.2
17
34
R53
ICD-10 Finland
Malaise and fatigue
2.9
6.1
42
199
K04.5
ICD-10 Finland
Chronic apical periodontitis
3.1
6.1
33
137
F41.09
ICD-10 Finland
UNS Panic Syndrome
8.9
6.0
12
15
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
31
45
9.36
21.69
1.4
2.0
2.71
2.64
mg/l
0.02
31
28
65
285
4.36
12.47
3.8
2.9
22.05
28.23
u/l
2.43
65
273
69
347
3.88
10.22
6.2
8.0
1.22
1.22
mmol/l
0.40
64
298
64
318
3.59
9.41
2.8
1.9
90.27
92.10
pmol/l
0.12
33
163
12
9
14.84
7.59
1.2
1.0
—
—
—
0
0
79
503
3.30
6.79
8.6
8.8
4.08
4.12
e9/l
0.06
66
436
43
200
2.95
6.53
4.5
3.6
1.02
1.02
kg/l
0.36
22
139
67
402
2.84
6.18
4.1
5.5
9.25
10.85
umol/l
1.13
62
384
10
13
8.37
4.97
2.5
4.3
0.41
0.00
index
—
5
5
43
225
2.54
4.96
2.6
2.0
2.24
2.67
mg/l
0.86
32
206
49
273
2.49
4.94
4.8
3.1
—
—
—
0
0
41
220
2.42
4.39
3.8
2.6
0.70
0.30
e6/l
0.27
31
160
68
460
2.36
4.21
4.6
3.6
0.00
0.00
estimate
-0.00
12
101
67
454
2.31
4.08
4.6
3.5
0.00
0.00
estimate
-0.00
12
100
12
29
4.53
3.84
5.4
2.2
25.16
23.80
mmol/l
0.77
12
29
14
40
3.88
3.78
5.9
3.1
4.16
4.23
kpa
0.07
14
40
44
260
2.19
3.64
1.6
1.3
0.53
3.01
u/ml
—
10
64
11
26
4.60
3.62
6.1
3.0
0.58
0.61
%
0.16
11
26
11
27
4.42
3.51
6.1
3.0
0.98
1.41
%
0.82
11
27
66
462
2.15
3.49
4.7
3.7
0.00
0.00
estimate
-0.00
12
99
14
48
3.21
3.45
1.6
2.0
—
—
—
0
0
97
827
3.27
3.33
4.9
4.0
4.41
4.65
mmol/l
2.08
91
780
95
787
3.17
3.25
16.7
10.9
92.78
92.04
ml/min/173m2
0.15
90
711
96
824
2.92
3.05
5.0
4.0
1.38
1.50
mmol/l
2.25
91
776
49
321
1.99
2.95
2.2
1.7
1.26
1.21
mmol/l
0.26
44
276
32
180
2.12
2.91
2.5
2.0
—
—
—
0
0
21
100
2.38
2.82
1.5
1.6
1141.41
1188.97
nmol/l
0.08
14
77
6
10
6.28
2.73
1.0
2.7
—
—
—
0
0
22
109
2.29
2.71
3.5
3.0
151.80
104.52
ng/l
0.11
15
61
11
36
3.29
2.66
1.7
1.9
—
—
—
0
0
9
26
3.69
2.55
1.3
1.2
395.89
346.23
mg/l
—
9
26
38
239
1.92
2.50
4.9
3.7
0.00
0.00
estimate
-0.00
11
95
11
38
3.11
2.50
1.5
1.1
—
—
—
0
0
14
58
2.63
2.49
1.4
1.4
200.40
243.74
miu/ml
—
7
31
23
121
2.15
2.45
3.3
2.3
2.94
3.60
e6/l
0.14
11
58
24
129
2.12
2.42
3.3
2.2
0.52
0.71
e6/l
0.28
12
67
26
146
2.04
2.34
2.3
1.9
—
—
—
0
0
49
344
1.80
2.24
4.5
3.4
0.00
0.00
estimate
-0.00
11
83
8
25
3.38
2.14
1.0
1.1
—
—
—
0
0
8
26
3.24
2.06
1.0
1.1
—
—
—
0
0
39
261
1.79
2.06
3.8
3.2
14.91
40.89
ng/l
1.02
25
145
19
102
2.05
1.91
2.9
2.4
1824.91
5580.43
u/l
—
7
44
30
189
1.82
1.91
3.4
4.1
1.77
8.16
mg/mmol
1.86
18
114
15
74
2.20
1.86
3.7
3.3
4.44
4.67
pmol/l
0.51
15
67
29
184
1.80
1.80
1.9
1.6
0.74
1.04
mg/l
0.34
21
135
28
179
1.77
1.69
1.3
1.4
15.83
26.70
iu/ml
—
8
44
84
720
1.83
1.69
4.1
3.9
—
—
—
0
0
5
14
3.69
1.63
17.4
8.1
4.00
3.89
mmol/l
—
5
14
13
64
2.18
1.62
1.5
1.4
—
—
—
0
0
7
28
2.60
1.48
1.6
1.4
93.71
98.21
%
—
7
28
5
16
3.23
1.45
1.2
1.2
—
—
—
0
0
5
16
3.23
1.45
1.0
1.2
—
—
—
0
0
6
23
2.70
1.39
1.3
1.3
138.67
188.00
%
—
6
23
6
23
2.70
1.39
4.5
3.8
25.77
24.37
mmol/l
—
6
23
11
54
2.16
1.38
1.3
1.3
—
—
—
0
0
12
63
2.02
1.29
1.3
1.2
172.69
462.58
u/ml
0.34
12
57
31
219
1.59
1.27
2.0
2.1
—
—
—
0
0
13
73
1.89
1.17
11.8
8.4
105.46
104.99
mmol/l
0.21
13
73
13
74
1.86
1.12
1.4
1.4
—
—
—
0
0
7
35
2.07
1.02
1.4
1.6
—
—
—
0
0
30
225
1.47
0.92
1.7
1.5
—
—
—
0
0
16
105
1.62
0.88
4.2
4.2
19.43
24.03
%
—
7
48
36
283
1.41
0.86
3.1
2.2
—
—
—
0
0
33
256
1.42
0.85
2.9
2.1
—
—
—
0
0
35
275
1.41
0.84
2.2
1.9
—
—
—
0
0
17
118
1.53
0.75
1.5
1.6
—
—
—
0
0
7
39
1.85
0.74
1.1
1.7
—
—
—
0
0
33
263
1.37
0.72
3.5
2.9
0.00
0.01
estimate
0.49
11
76
23
172
1.43
0.72
1.4
1.3
1.90
7.76
u/ml
—
8
63
11
69
1.66
0.71
1.1
1.0
—
—
—
0
0
10
61
1.71
0.71
4.5
1.6
547.40
334.80
mu/l
—
10
52
18
129
1.48
0.69
2.0
1.7
355555863.50
431.49
pmol/l
0.48
18
109
5
30
1.70
0.62
17.4
15.3
0.80
0.68
%
—
5
30
83
769
1.38
0.62
24.7
15.1
13.04
13.38
%
3.94
83
761
13
96
1.40
0.44
1.2
1.2
84.95
174.89
u/ml
—
6
35
5
32
1.59
0.43
17.4
14.5
1.00
1.25
%
—
5
32
11
79
1.44
0.42
4.8
5.7
—
—
—
0
0
7
105
0.64
0.41
1.4
1.5
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
49
439
1.22
0.41
2.7
2.8
—
—
estimate
—
0
0
10
71
1.45
0.41
1.2
1.5
—
—
—
0
0
5
78
0.62
0.37
1.6
1.7
—
—
—
0
0
6
41
1.49
0.37
1.7
1.9
—
—
—
0
0
6
43
1.42
0.35
1.7
2.0
—
—
—
0
0
6
45
1.35
0.34
1.3
1.3
—
—
—
0
0
22
184
1.25
0.34
3.0
2.7
329.36
312.16
umol/l
0.42
22
161
10
129
0.75
0.30
1.3
1.5
—
—
—
0
0
8
66
1.23
0.27
4.1
2.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
106.15
—
0
11
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
2.1
—
5.48
—
0
13
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
5.2
—
1653.57
—
0
14
5
69
0.71
0.17
2.6
1.9
—
—
—
0
0
5
45
1.12
0.10
1.0
1.3
—
—
—
0
0
6
54
1.12
0.09
1.5
4.1
1.23
1.22
mmol/l
—
6
46
5
62
0.80
0.08
4.2
3.4
0.43
0.13
e6/l
—
5
62
5
63
0.78
0.08
2.0
1.6
51.23
53.89
ug/l
—
5
63
0
8
0.00
0.00
0.0
1.3
—
1.11
—
0
8
0
8
0.00
0.00
0.0
1.3
—
1.78
—
0
8
0
6
0.00
-0.00
0.0
2.3
—
159.83
—
0
6
0
6
0.00
-0.00
0.0
1.5
—
202.67
—
0
6
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
47.40
—
0
5
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
5
51
0.98
-0.00
1.8
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.6
—
123.44
—
0
9
0
6
0.00
-0.00
0.0
1.3
—
101.50
—
0
6
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint F5_NIGHTMARES and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have F5_NIGHTMARES.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: F5_NIGHTMARES – Nightmares
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data